Immuno oncology News and Research

RSS

Early gut bacteria may help protect babies from respiratory infections

A baby's makeup of gut bacteria - their microbiome - which starts to form as soon as they are born, could help protect against viral infections later in childhood, a new study suggests.

5 Jun 2025

Immunotherapy before surgery boosts long term survival in lung cancer, trial shows

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard chemotherapy before surgery had improved long term survival compared to those who received chemotherapy alone, at 5 years after completing treatment.

2 Jun 2025

New insights into decades-old bladder cancer treatment offers clues for immunotherapy

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.

29 May 2025

Unlocking live single-cell functional insights

Discover how Bruker is advancing live single-cell functional analysis, helping to accelerate breakthroughs in immunology and beyond.

From Bruker Cellular Analysis 16 May 2025

CAR-T cell therapy linked to brain fog in cancer patients

After treatment with CAR-T cells - immune cells engineered to attack cancer - patients sometimes tell their doctors they feel like they have "brain fog," or forgetfulness and difficulty concentrating.

12 May 2025

Bruker to launch Beacon Discovery™ at AACR 2025, expanding access to live single-cell functional analysis

Bruker Corporation today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.

From Bruker Cellular Analysis 25 Apr 2025

Novel cancer immunotherapy approach could complement existing CAR-T treatments

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.

24 Apr 2025

New approach targets cell surface protein to treat leukemia and solid tumors

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

23 Apr 2025

New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer

Novigenix, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic urothelial cancer.

13 Mar 2025

Study elucidates mechanism behind bacterial cancer therapy

A research team led by Prof. Liu Chenli from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (CAS) and Prof. Xiao Yichuan from the Shanghai Institute of Nutrition and Health of CAS elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain.

3 Mar 2025

Study finds anti-correlation of KLRG1 and PD-1 expression in tumor fighting T cells

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells."

21 Jan 2025

Bacterial toxin may fuel colorectal cancer metastasis

A toxin in the bacteria that's one of the most common causes of foodborne illness accelerates the spread of colorectal tumors to other parts of the body, a study led by UF Health Cancer Center researchers and international collaborators has found.

6 Dec 2024

New study links specific E. coli strains to higher cancer incidence rates

Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria.

6 Dec 2024

Study links cell death pathway to cancer resistance and growth

A new study has uncovered an unexpected way cancer cells can escape the immune system, making it harder for treatments to work. The study, published in Cancer Cell, explains how a type of cancer cell death can actually make tumors grow faster by turning off the immune system's ability to fight the cancer.

27 Nov 2024

Tagomics announces a multiomic profiling co-marketing agreement with Agilent

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has entered into a strategic co-marketing agreement with Agilent Technologies, a leading tools provider in the genomics sector.

From Tagomics Ltd. 26 Nov 2024

Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study

Nomic Bio and PICI collaborate to quantify protein biomarkers in cancer immunotherapy, enhancing understanding of patient responses and treatment resistance.

From Nomic 12 Nov 2024

New insights into the role of innate immunity in tumor initiation

Along with defending against pathogens, the body's innate immune system helps to protect the stability of our genomes in unexpected ways - ways that have important implications for the development of cancer, researchers at Memorial Sloan Kettering Cancer Center (MSK) are discovering.

5 Nov 2024

Researchers identify mechanism of immune suppression in ovarian cancer

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The study, published Oct. 23 in Nature, points toward a promising new immunotherapy approach for ovarian cancer, which is notoriously aggressive and hard to treat.

24 Oct 2024

Researchers discover how ovarian tumors cripple immune cells

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the energy supply T cells depend on.

23 Oct 2024

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers.

16 Oct 2024